Research ExplorerPublicationsPerformance evaluation and multicentre study of a von Willeb...

Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin

Standard

Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin. / Patzke, Juergen; Budde, Ulrich; Huber, Andreas; Méndez, Adriana; Muth, Heidrun; Obser, Tobias; Peerschke, Ellinor; Wilkens, Matthias; Schneppenheim, Reinhard.

In: BLOOD COAGUL FIBRIN, Vol. 25, No. 8, 01.12.2014, p. 860-870.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Patzke, J, Budde, U, Huber, A, Méndez, A, Muth, H, Obser, T, Peerschke, E, Wilkens, M & Schneppenheim, R 2014, 'Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin', BLOOD COAGUL FIBRIN, vol. 25, no. 8, pp. 860-870. https://doi.org/10.1097/MBC.0000000000000169

APA

Patzke, J., Budde, U., Huber, A., Méndez, A., Muth, H., Obser, T., Peerschke, E., Wilkens, M., & Schneppenheim, R. (2014). Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin. BLOOD COAGUL FIBRIN, 25(8), 860-870. https://doi.org/10.1097/MBC.0000000000000169

Vancouver

Patzke J, Budde U, Huber A, Méndez A, Muth H, Obser T et al. Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin. BLOOD COAGUL FIBRIN. 2014 Dec 1;25(8):860-870. https://doi.org/10.1097/MBC.0000000000000169

Bibtex

@article{7ac735189a844512a274d74603fd095a,
title = "Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin",
abstract = "The functional activity of von Willebrand factor (VWF) is most frequently measured by using the ristocetin cofactor assay (VWF:RCo). However, the method's drawbacks include unsatisfactory precision, sensitivity and availability of automated system applications. We have developed an alternative assay (INNOVANCE VWF Ac) that is based on the binding of VWF to recombinant glycoprotein Ib (GPIb). Two gain-of-function mutations were introduced into a GPIb fragment, allowing an assay format without ristocetin. Fully automated assay applications are available for the BCS/BCS XP systems and the Sysmex CS-2000i, Sysmex CA-7000, Sysmex CA-1500 and Sysmex CA-560 systems.The INNOVANCE VWF Ac assay measuring range extends from 4 to 600% VWF for all systems except the Sysmex CA-560 system. Within-device precision values were found to be between 2 and 7%. The limit of detection was below 2.2% VWF. In a study on the BCS XP system, a total number of 580 sample results yielded a correlation to the VWF:RCo assay of r equal to 0.99 (slope = 0.96). Very similar results were observed when von Willebrand disease samples type 1, 2A, 2B, 2M, 2N and 3 were investigated with the new assay and the VWF:RCo assay. The excellent performance data and comparability to VWF:RCo, together with the ease of use, led us to the conclusion that the ristocetin cofactor assay can be replaced by the new GPIb-binding assay to reliably diagnosing patients with von Willebrand disease.",
author = "Juergen Patzke and Ulrich Budde and Andreas Huber and Adriana M{\'e}ndez and Heidrun Muth and Tobias Obser and Ellinor Peerschke and Matthias Wilkens and Reinhard Schneppenheim",
year = "2014",
month = dec,
day = "1",
doi = "10.1097/MBC.0000000000000169",
language = "English",
volume = "25",
pages = "860--870",
journal = "BLOOD COAGUL FIBRIN",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

RIS

TY - JOUR

T1 - Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin

AU - Patzke, Juergen

AU - Budde, Ulrich

AU - Huber, Andreas

AU - Méndez, Adriana

AU - Muth, Heidrun

AU - Obser, Tobias

AU - Peerschke, Ellinor

AU - Wilkens, Matthias

AU - Schneppenheim, Reinhard

PY - 2014/12/1

Y1 - 2014/12/1

N2 - The functional activity of von Willebrand factor (VWF) is most frequently measured by using the ristocetin cofactor assay (VWF:RCo). However, the method's drawbacks include unsatisfactory precision, sensitivity and availability of automated system applications. We have developed an alternative assay (INNOVANCE VWF Ac) that is based on the binding of VWF to recombinant glycoprotein Ib (GPIb). Two gain-of-function mutations were introduced into a GPIb fragment, allowing an assay format without ristocetin. Fully automated assay applications are available for the BCS/BCS XP systems and the Sysmex CS-2000i, Sysmex CA-7000, Sysmex CA-1500 and Sysmex CA-560 systems.The INNOVANCE VWF Ac assay measuring range extends from 4 to 600% VWF for all systems except the Sysmex CA-560 system. Within-device precision values were found to be between 2 and 7%. The limit of detection was below 2.2% VWF. In a study on the BCS XP system, a total number of 580 sample results yielded a correlation to the VWF:RCo assay of r equal to 0.99 (slope = 0.96). Very similar results were observed when von Willebrand disease samples type 1, 2A, 2B, 2M, 2N and 3 were investigated with the new assay and the VWF:RCo assay. The excellent performance data and comparability to VWF:RCo, together with the ease of use, led us to the conclusion that the ristocetin cofactor assay can be replaced by the new GPIb-binding assay to reliably diagnosing patients with von Willebrand disease.

AB - The functional activity of von Willebrand factor (VWF) is most frequently measured by using the ristocetin cofactor assay (VWF:RCo). However, the method's drawbacks include unsatisfactory precision, sensitivity and availability of automated system applications. We have developed an alternative assay (INNOVANCE VWF Ac) that is based on the binding of VWF to recombinant glycoprotein Ib (GPIb). Two gain-of-function mutations were introduced into a GPIb fragment, allowing an assay format without ristocetin. Fully automated assay applications are available for the BCS/BCS XP systems and the Sysmex CS-2000i, Sysmex CA-7000, Sysmex CA-1500 and Sysmex CA-560 systems.The INNOVANCE VWF Ac assay measuring range extends from 4 to 600% VWF for all systems except the Sysmex CA-560 system. Within-device precision values were found to be between 2 and 7%. The limit of detection was below 2.2% VWF. In a study on the BCS XP system, a total number of 580 sample results yielded a correlation to the VWF:RCo assay of r equal to 0.99 (slope = 0.96). Very similar results were observed when von Willebrand disease samples type 1, 2A, 2B, 2M, 2N and 3 were investigated with the new assay and the VWF:RCo assay. The excellent performance data and comparability to VWF:RCo, together with the ease of use, led us to the conclusion that the ristocetin cofactor assay can be replaced by the new GPIb-binding assay to reliably diagnosing patients with von Willebrand disease.

U2 - 10.1097/MBC.0000000000000169

DO - 10.1097/MBC.0000000000000169

M3 - SCORING: Journal article

C2 - 25192242

VL - 25

SP - 860

EP - 870

JO - BLOOD COAGUL FIBRIN

JF - BLOOD COAGUL FIBRIN

SN - 0957-5235

IS - 8

ER -